Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $255M | $240M | $295M | $322M | $350M | $438M | $499M | $644M | $732M | $720M |
| Revenue growth | — | -5.9% | 22.7% | 9.4% | 8.5% | 25.1% | 14.0% | 29.1% | 13.6% | -1.7% |
| Gross profit | $104M | $90.5M | $107M | $132M | $143M | $200M | $249M | $351M | $374M | $356M |
| Gross margin | 40.8% | 37.7% | 36.3% | 40.9% | 41.0% | 45.6% | 49.9% | 54.5% | 51.1% | 49.5% |
| Operating income | $15.4M | -$1.27M | -$8.62M | -$39.0K | $11.0M | $69.9M | $107M | $197M | $205M | $140M |
| Operating margin | 6.0% | -0.5% | -2.9% | -0.0% | 3.1% | 16.0% | 21.5% | 30.6% | 28.1% | 19.5% |
| Net income | $9.82M | $3.65M | -$5.74M | $48.9M | $1.40M | $62.1M | $91.4M | $138M | $160M | $98.1M |
| Net margin | 3.8% | 1.5% | -1.9% | 15.2% | 0.4% | 14.2% | 18.3% | 21.3% | 21.8% | 13.6% |
| EPS (diluted) | $0.21 | $0.08 | -$0.12 | $0.98 | $0.03 | $1.25 | $1.74 | $2.60 | $3.06 | $2.03 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $38.6M | $39.2M | $38.2M | $41.8M | $57.3M | $98.0M | $89.2M | $184M | $213M | $156M |
| Capital expenditures | $21.4M | $35.1M | $46.8M | $41.6M | $33.9M | $27.5M | $24.0M | $38.2M | $41.0M | $34.9M |
| Free cash flow | $17.2M | $4.11M | -$8.62M | $207K | $23.4M | $70.5M | $65.1M | $145M | $172M | $121M |
| Share buybacks | $9.91M | $30.7M | $25.0M | $22.3M | $24.4M | $28.9M | $39.9M | $58.1M | $85.5M | $75.6M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $72.4M | $65.6M | $86.3M | $73.7M | $92.6M | $126M | $156M | $144M | $152M | $170M |
| Total assets | $428M | $451M | $514M | $587M | $631M | $672M | $742M | $1.51B | $1.58B | $1.63B |
| Total liabilities | $98.5M | $117M | $149M | $159M | $183M | $226M | $213M | $873M | $845M | $840M |
| Long-term debt | $36.0M | $45.7M | $49.1M | $46.3M | $45.9M | $78.2M | $76.6M | $603M | $614M | $620M |
| Shareholders' equity | $327M | $334M | $364M | $428M | $449M | $446M | $529M | $639M | $732M | $789M |
| Retained earnings | $70.9M | $72.6M | $67.5M | $116M | $118M | $180M | $272M | $409M | $569M | $667M |
| Shares (wtd avg diluted) | 47.5M | 48.4M | 46.4M | 49.9M | 49.1M | 49.8M | 52.4M | 53.0M | 52.1M | 48.2M |
Every figure is extracted from Amphastar Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.